Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 403-404, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spencer, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spencer, K.
Related Collections
Right arrow Laboratory Management
Right arrow Molecular Diagnostics and Genetics
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2002;48:403-404.)
© 2002 American Association for Clinical Chemistry, Inc.

Editorial

Point-of-Care Screening for Chromosomal Anomalies in the First Trimester of Pregnancy

Kevin Spencer1a

1 Endocrine Unit, Department of Clinical Biochemistry, Harold Wood Hospital, Gubbins Lane, Romford, Essex RM3 0BE, United Kingdom

aFax 44-1708-381486, E-mail KevinSpencer1@cs.com

Since the serendipitous finding almost 20 years ago of a reduced concentration of maternal serum {alpha}-fetoprotein (MSAFP) in an index case of a second-trimester pregnancy complicated by trisomy 18 (1) and the subsequent confirmation of this finding in other pregnancies complicated by trisomy 21, there has been a gradual improvement in trisomy 21 screening efficiency as better markers have been identified. Screening using a combination of maternal age, MSAFP, and maternal serum free ß-human chorionic gonadotropin (ß-hCG) or total hCG has enabled trisomy 21 detection rates of 65–70% (for a 5% screen-positive rate) to be achieved in second-trimester prospective screening (2)(3). Although the use of additional markers such as unconjugated estriol and dimeric inhibin-A have been proposed, modeling predicts only an additional 5% detection (4), and no large-scale prospective data have been published with a four-marker combination.

In the past decade, research energies have largely focused on the first trimester of pregnancy. The identification of suitable maternal serum biochemical markers such as free ß-hCG (5) and pregnancy-associated plasma protein A (PAPP-A) (6) led this advance. The development of improved ultrasound imaging techniques, however, allowed the identification of nuchal translucency thickness as the major marker of chromosomal anomalies in the first trimester. With measurements performed in a standardized way (defined by the Fetal Medicine Foundation; www.fetalmedicine.com) by suitably trained sonographers, trisomy 21 detection rates in combination with maternal age have reached 73% (for a 5% screen-positive rate) in multicenter prospective intervention studies (7). A combination of nuchal translucency and the two first-trimester serum markers has been shown to increase this . . . [Full Text of this Article]


Acknowledgments


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.